Age and outcome with contemporary thrombolytic therapy: Results from the GUSTO-I trial

Circulation

Volumn 94, Issue 8, 1996, Pages 1826-1833

  White, Harvey D ^a   Barbash, Gabriel I ^b   Califf, Robert M ^c   Simes, R John ^d   Granger, Christopher B ^c   Weaver, W Douglas ^e   Kleiman, Neal S ^f   Aylward, Philip E ^g   Gore, Joel M ^h   Vahanian, Alec ⁱ   Lee, Kerry L ^c   Ross, Allan M ^j   Topol, Eric J ^k  

^a GREEN LANE HOSPITAL   (New Zealand)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g FLINDERS MEDICAL CENTRE   (Australia)

^h UNIVERSITY OF MASSACHUSETTS   (United States)

ⁱ HÔPITAL TENON   (France)

^j GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

aging; streptokinase; thrombolysis; tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; AGE; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; GERIATRIC CARE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 10244242679     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.8.1826     Document Type: Article

References (35)

1. Stason WB, Sanders CA, Smith HC. Cardiovascular care of the elderly: economic consideration. J Am Coll Cardiol. 1987;10: 18A-21A.
2. Roig E, Castaner A, Simmons B, Patel R, Ford E, Cooper R. In-hospital mortality rates from acute myocardial infarction by race in US hospitals: findings from the National Hospital Discharge Survey. Circulation. 1987;76:280-288.
3. Morris RM, Brandt PWT, Caughey DE, Lee AJ, Scott PJ. A new coronary prognostic index. Lancet. 1969;1:274-278.
4. Hillis LD, Forman S, Braunwald E, and the Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1990;16:313-315.
5. Maggioni AP, Franzosi JG, Santoro E, White H, Van de Werf F, Tognoni G, on behalf of the GISSI-2 and International Study Groups. Analysis of the risk of stroke in 20,891 patients with acute myocardial infarction following thrombolytic and antithrombotic treatment. N Engl J Med. 1992;327:1-6.
6. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J. 1993;307:349-353.
7. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
9. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-874.
10. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Lancet. 1990;335:1175-1178.
11. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med. 1979;301:797-802.
12. Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson AN, Goldman L. Cost effectiveness of thrombolytic therapy with Streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992;327:7-13.
13. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction Trials. J Am Coll Cardiol. 1992;20:1452-1459.
14. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
15. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase 1 findings. N Engl J Med. 1985;312:932-936.
16. Anderson JL, Marshall HW, Bray BE, Lutz JR, Frederick PR, Yanowitz FG, Datz FL, Klausner SC, Hagan AD. A randomized trial of intracoronary Streptokinase in the treatment of acute myocardial infarction. N Engl J Med. 1983;308:1312-1318.
17. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activation for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
18. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
19. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapaport E, Fuster V, Reeves TJ, Karp RB, Russell RO Jr. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990;16:249-292.
20. Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, Ho MT, Cobb LA, Kennedy JW, Wirkus MS, for the MITI Project Group, Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol. 1991;18:657-662.
21. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
22. Fuster V. Coronary thrombolysis: a perspective for the practicing physician. N Engl J Med. 1993;329:723-725.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
24. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
25. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-1528.
26. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM, for the GUSTO-I Investigators. Stroke after thrombolytic therapy: mortality and functional outcomes in the GUSTO-I trial. Circulation. 1995;92:2811-2818.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Smith PL. Splines as a useful and convenient statistical tool. Am Statistician. 1979;33:57-62.
29. Stone CJ, Koo C. Additive splines in statistics. In: Proceedings of the Statistical Computing Section. 1985:45-48.
30. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. In: Proceedings of the 11th Annual SAS Users Group International Conference. 1986:646-651.
31. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
32. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
33. Harrison JK, Califf RM, Woodlief LH, Kereiakes D, George BS, Stack RS, Ellis SG, Lee KL, O'Neill W, Topol EJ, for the TAMI Study Group. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction: analysis of determinants of improvement. Circulation. 1993;87:1531-1541.
34. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409-422.
35. Mark DB, Hlatky MA, Califf RM, Naylor D, Lee KL, Armstrong PW, Barbash GI, White HD, Simoons ML, Nelson C, Clapp-Channing N, Knight D, Harrell FE Jr, Simes RJ, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator versus streptokinase for acute myocardial infarction: results from the GUSTO randomized trial. N Engl J Med. 1995;332:1418-1424.